biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Prothena

<< Previous

Bullboard Posts

Next >>

Comment by DeadMonkeyon May 04, 2023 11:30am

70 Views

Post# 35430118

RE:Prothena

you so sure about that? 100% certain? drug companies make improvements to their drugs all of the time.largely goes unnoticed by most except those paying close attention to patents, just because they didn't say their work was a result of xb3 doesnt mean that it wasnt.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale